 - Evaluate the impact of neoadjuvant sargramostim GM-CSF and thalidomide on pathologic response histologic P0, margin positivity, capsular penetration, prostate-specific antigen PSA response, and other investigational endpoints in patients with high-risk prostate cancer undergoing prostatectomy. 